StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$31.20−1.67 (-5.08%)

Close on Nov 18, 2026Market cap $1.73BP/E –Yield –

Maze Therapeutics shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Maze Therapeutics's shares outstanding was 59M at Jun 30, 2026. For fiscal 2025 it was 43M, up 1474.0% from the year before.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 202543M+1474.0%
FY2024Dec 31, 20243M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 202659M+34.7%
Q1 FY2026Mar 31, 202654M+88.3%
Q4 FY2025Dec 31, 202554M+2100.2%
Q3 FY2025Sep 30, 202546M+1794.9%
Q2 FY2025Jun 30, 202544M+915.2%
Q1 FY2025Mar 31, 202529M+1125.2%
Q4 FY2024Dec 31, 20242M–
Q3 FY2024Sep 30, 20242M–
Q2 FY2024Jun 30, 20244M–
Q1 FY2024Mar 31, 20242M–

More Maze Therapeutics figures

See a number that looks wrong?